Karen WenChief Strategy and Product Development Officer at GenomeFrontier Therapeutics, Inc., Taiwan
Karen Wen is a pioneer in the field of biological product development specialized in process development and PIC/S GMP production including peptide, proteins, monoclonal antibodies, DNA vaccine and antibody-cell conjugate product and is expanding her professionals in the area of gene and cellular therapy. In this presentation, Karen will share the company’s proprietary technology, a non-viral system for gene(s) delivery in the CAR-T therapy. This high- quality CAR+ technology is a disruptive innovation and expected to provide the better opportunity for larger gene loading capacity for solid tumor treatment. This convivence and cost effectiveness of this non-viral gene delivery system would lead the gene and cellular therapy into the new era.